Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
03 März 2025 05:12PM

Alzchem Group invites you to the Creatine Conference 2025: Munich is becoming a hotspot for creatine research

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2094409


EQS-Media / 03.03.2025 / 17:12 CET/CEST

Alzchem Group invites you to the Creatine Conference 2025: Munich is becoming a hotspot for creatine research

The Alzchem Group is once again bringing together the brightest minds in creatine research in 2025 – in the heart of Munich. From March 12 to 15, 2025, the Meliá Hotel will be transformed into a meeting place for scientists, health and nutrition experts, and anyone else interested in learning more about the versatile benefits of creatine.   

The conference will be held in a hybrid format – live on site and online – so that everyone can attend.  

The event is organized by the Creatine for Health Scientific Advisory Board of Alzchem Group AG, the Exercise and Sport Nutrition Laboratory of Texas A&M University and the DBSS Research Division. Together, they provide a high-level platform to highlight the latest findings and innovations in creatine supplementation, from performance enhancement to longevity.    
 

The future starts here
On all four days of the event, participants can look forward to exciting expert presentations on topics such as:   

  • Creatine as a way to combat fatigue symptomes
  • The role of creatine in women’s health 
  • Creatine to support general well-being 
  • How creatine can support cognitive performance 
  • Creatine for a healthy ageing  

The program will be complemented by interactive panel discussions – a perfect opportunity to engage with experts, gain new insights and immerse yourself in the world of creatine research.  
 

Expertise, innovation and networking  
“We at the Alzchem Group are thrilled to be bringing the Creatine Conference 2025 to Munich. This is where the most renowned minds in science, medicine and sports nutrition gather to present groundbreaking discoveries and actively shape the future of health and well-being. This conference is a must for anyone interested in the many uses of creatine – be it for athletic performance, cognitive function or general well-being,” says Martina Spitzer, CSO of the Alzchem Group.   

The organizers warmly invite experts from the fields of medicine, nutrition, sports science and wellness, as well as young researchers, business delegates and students. Of course, all other interested parties are always welcome. Participants can earn credits for continuing education units (CEUs) and continuing medical education (CMEs).  
 

Learn from the best: how to participate
Do you want to be there and benefit from the latest findings? Further information on registration and the detailed program is available here.   

You also have the opportunity to participate in the Creatine Conference 2025 online.   

Find out more and get your ticket now.   

Do you have research to share? Submit your abstract now! Deadline: February 17, 2025   
https://forms.gle/kDfLj2kRkhCTnKdS9  
 

For more information, visit:
www.creatineforhealth.com 
Creatine For Health - YouTube  
 

New book “Creatine – Muscle Metabolism, Fitness, Health & Longevity” explains the many benefits of creatine   
Creatine is much more than just a supplement for athletes: the substance plays a central role in muscle metabolism and offers numerous health benefits. The new book “Creatine – Muscle Metabolism, Fitness, Health & Longevity” by Prof. Dr. Jürgen Giessing and Dr. Robert Percy Marshall provides a well-founded, easy-to-understand presentation of the latest scientific findings on creatine and its many possible applications.  
 

About Alzchem
Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem offers answers to various global developments such as climate change, population growth and increasing life expectancy. We deliver solutions through brands and products of the highest quality and through a sustainable vision to help shape global developments.

The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

Alzchem Group AG’s broad product range includes dietary supplements, precursors for PCR tests and pharmaceutical raw materials. These offerings are the company’s response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.

The company employs around 1,730 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and England. Alzchem generated Group sales of EUR 554.2 million and EBITDA of EUR 105.3 million in 2024.

 



End of Media Release


Issuer: Alzchem Group AG
Key word(s): Health

03.03.2025 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 2094409

 
End of News EQS Media

2094409  03.03.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2094409&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2019 2020 2021 2022 2023 2024 2025e
Umsatzerlöse1 376,07 379,26 422,29 542,22 540,65 554,23 580,00
EBITDA1,2 50,08 53,81 62,05 61,44 81,37 105,27 113,00
EBITDA-Marge3 13,32 14,19 14,69 11,33 15,05 18,99 19,48
EBIT1,4 30,59 30,71 37,57 35,90 55,47 78,95 86,00
EBIT-Marge5 8,13 8,10 8,90 6,62 10,26 14,25 14,83
Jahresüberschuss1 18,15 19,87 27,76 30,22 34,79 54,25 59,00
Netto-Marge6 4,83 5,24 6,57 5,57 6,44 9,79 10,17
Cashflow1,7 43,63 48,71 43,02 -4,24 72,67 105,15 86,00
Ergebnis je Aktie8 1,77 1,94 2,72 2,96 3,40 5,31 5,85
Dividende8 0,75 0,77 1,00 1,05 1,20 1,80 1,80
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: RSM Ebner Stolz

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
Alzchem Group
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
A2YNT3 DE000A2YNT30 AG 1.381,95 Mio € Kaufen 8FWJ2HC2+23
* * *
KGV 2026e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
22,86 14,68 1,56 45,88 6,41 13,14 2,49
Dividenden
Dividende '2023
in €
Dividende '2024
in €
Dividende '2025e
in €
Div.-Rendite '2025e
in %
1,20 1,80 1,80 1,33%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
05.05.2026 30.04.2026 31.07.2026 30.10.2025 27.02.2026
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-4,10%
135,80 €
ATH 167,20 €
-6,48% +2,41% +138,25% +136,59% +4.698,59%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2025 · Made in Germany          
Die Analyse-Manufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 von Gereon Kruse #BGFL